NCT07543510 2026-04-22
Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma
Third Affiliated Hospital, Sun Yat-Sen University
Phase NA Not yet recruiting
Clinical Trials
19 trialsNCT07543783 2026-04-22
Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by TACE-HAIC
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT07544121 2026-04-22
Effect of Babao Dan Capsule Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis
Nanfang Hospital, Southern Medical University
Phase NA Not yet recruiting
NCT07487402 2026-04-21
Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma
Zhejiang University
Phase EARLY_PHASE1 Not yet recruiting
NCT07535840 2026-04-17
A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma
Tongji Hospital
Phase NA Not yet recruiting
NCT07537777 2026-04-17
Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy
Nanfang Hospital, Southern Medical University
Phase 2 Not yet recruiting
NCT07537946 2026-04-17
Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer
Tongji Hospital
Phase 3 Not yet recruiting
NCT07537959 2026-04-17
Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases
Tongji Hospital
Phase NA Not yet recruiting
NCT07537972 2026-04-17
Denosumab Strategy for Liver Cancer With Bone Metastases
Tongji Hospital
Phase 2 Not yet recruiting
NCT07522411 2026-04-13
Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma
Tongji Hospital
Phase 1/2 Not yet recruiting
NCT07518706 2026-04-09
Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07514429 2026-04-07
RELEVANT-HCC
Asan Medical Center
Phase 2 Not yet recruiting
NCT07514455 2026-04-07
RECOMEND
Asan Medical Center
Phase 2 Not yet recruiting
NCT07515469 2026-04-07
A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07511504 2026-04-06
Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma
OHSU Knight Cancer Institute
Phase 2 Not yet recruiting
NCT07075120 2026-03-31
Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer
University of Hawaii
Phase 1 Not yet recruiting
NCT06971848 2026-03-30
ETCABIO
University Hospital, Angers
Phase NA Not yet recruiting
NCT07495579 2026-03-27
REVIVE
Asan Medical Center
Phase 2 Not yet recruiting
NCT07495735 2026-03-27
Intelligence System for Predicting Atezolizumab-Bevacizumab Response and Clinical Outcomes in Unresectable Hepatocellular Carcinoma
First Affiliated Hospital of Wenzhou Medical University
Not yet recruiting